Vaccine targets swine flu as FDA targets fakes

As the first U.S. doses of government-contracted H1N1 swine flu vaccine were produced last week-via egg-less insect cell technology-the FDA reminds the public to be wary of Internet sites and other promotions for products that claim to diagnose, prevent, treat or cure the virus.

Connecticut-based Protein Sciences continues to produce its recombinant influenza vaccine, fulfilling its obligation under a $35-million grant from the U.S. Department of Health and Human Services. If all goes well, the contract could be extended for five years at a sum of $147 million, according to an HHS announcement.

Production involves the extraction of a gene from a flu virus and then its insertion into a Baculovirus, which multiplies quickly. Cells are then purified to become part of a human vaccine. The technique promises quicker vaccine production than is available via traditional egg-based methods, hence the HHS interest in light of pandemic eventuality. 

Separately, the Fort Worth, TX-based Star-Telegram reports that the FDA has identified some 73 fraudulent swine flu products. It's favorite: "the Photon Genie, an ‘electromedicine instrument' said to strengthen the immune system by using ‘life-nourishing photobiotic energy.'"

- read the HHS announcement
- here's an article on the vaccine
- and here's the Star-Telegram article about fraudulent products

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.